Redeye comment's on Hansa Biopharma's CMD. Clinical data from imlifidase across clinical trials were discussed. KOLs discussed how it is used in practice and how it can transform the life of ultra-highly sensitised patients. Finally, the market strategy and pipeline were discussed.
LÄS MER
